The ears of big pharma and large biotech firms looking to progress promising but non-priority R&D assets will have pricked up on the news that transatlantic life sciences investment firm Abingworth has closed its new fund focused on clinical co-development at a whopping $582m.
Abingworth Offers Home For Big Pharma Pipeline Projects
Closes $582m Clinical Co-Development Fund
The UK-headquartered life sciences investment firm has comfortably exceeded its target of $350m for a fund dedicated to taking on late-stage products, incurring all the clinical and regulatory risk and receiving a pre-negotiated return once the drug is approved.
More from Financing
More from Business
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.